secwatch / observer
8-K filed June 13, 2023, 7:59 PM ET ticker AKBA CIK 0001517022
leadership confidence high sentiment neutral materiality 0.70

CFO David Spellman resigns; Ellen Snow appointed as new CFO effective July 17, 2023

Akebia Therapeutics, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change (interim)

John Butler

interim principal financial officer and principal accounting officer
AKBA · Akebia Therapeutics, Inc.
Effective
2023-06-23
Filed
June 13, 2023, 7:59 PM ET
John Butler, the Company’s President and Chief Executive Officer, will act as interim principal financial officer and principal accounting officer from the Transition Date until the Effective Date.
Appointed

Ellen Snow

Senior Vice President, Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer
AKBA · Akebia Therapeutics, Inc.
Effective
2023-07-17
Filed
June 13, 2023, 7:59 PM ET
On June 12, 2023 , the Company announced that Ellen Snow will succeed Mr. Spellman as the Company’s Senior Vice President, Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer, effective July 17, 2023 (the “Effective Date”).
Departed

David A. Spellman

Senior Vice President, Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer
AKBA · Akebia Therapeutics, Inc.
Effective
2023-06-23
Successor
Ellen Snow
Filed
June 13, 2023, 7:59 PM ET
On June 9, 2023, David A. Spellman, Senior Vice President, Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer of Akebia Therapeutics, Inc. (the “Company”), notified the Company of his intent to resign.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

John Butler changed role as interim principal financial officer and principal accounting officer at Akebia Therapeutics, Inc..

Action
designated as interim
Role
interim principal financial officer and principal accounting officer
Exact text from the filing
John Butler, the Company’s President and Chief Executive Officer, will act as interim principal financial officer and principal accounting officer from the Transition Date until the Effective Date.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Ellen Snow was appointed as Senior Vice President, Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer at Akebia Therapeutics, Inc..

Action
appointed
Role
Senior Vice President, Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer
Exact text from the filing
On June 12, 2023 , the Company announced that Ellen Snow will succeed Mr. Spellman as the Company’s Senior Vice President, Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer, effective July 17, 2023 (the “Effective Date”).
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

David A. Spellman resigned as Senior Vice President, Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer at Akebia Therapeutics, Inc..

Action
resigned
Role
Senior Vice President, Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer
Exact text from the filing
On June 9, 2023, David A. Spellman, Senior Vice President, Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer of Akebia Therapeutics, Inc. (the “Company”), notified the Company of his intent to resign.
View on SEC.gov

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001517022-23-000017
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.